{"id":"NCT02385240","sponsor":"Padagis LLC","briefTitle":"Comparative Safety and Efficacy of Two Rosacea Products in the Treatment of Facial Erythema of Rosacea","officialTitle":null,"status":"COMPLETED","phase":"PHASE3","dates":{"start":"2015-03","primaryCompletion":"2015-12","completion":"2015-12","firstPosted":"2015-03-11","resultsPosted":"2020-12-14","lastUpdate":"2021-10-22"},"enrollment":552,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Rosacea"],"interventions":[{"type":"DRUG","name":"Brimonidine Topical Gel, 0.33 percent (Perrigo)","otherNames":["Perrigo product"]},{"type":"DRUG","name":"Brimonidine Topical Gel, 0.33 percent (Reference)","otherNames":["Reference Listed Drug Product"]},{"type":"DRUG","name":"Placebo gel","otherNames":[]}],"arms":[{"label":"Test product","type":"EXPERIMENTAL"},{"label":"Reference Product","type":"ACTIVE_COMPARATOR"},{"label":"Placebo gel","type":"PLACEBO_COMPARATOR"}],"summary":"To compare safety and efficacy of Perrigo's rosacea drug product compared to an FDA approved rosacea drug product in the treatment of facial erythema of rosacea.","primaryOutcome":{"measure":"Proportion of Subjects With Composite Success","timeFrame":"Day 15 at hour 6","effectByArm":[{"arm":"Test Product","deltaMin":60,"sd":null},{"arm":"Reference Product","deltaMin":58,"sd":null},{"arm":"Placebo Gel","deltaMin":23,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":null}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":0,"countries":[]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":1,"n":183},"commonTop":[]}}